Clinical Trial Results: A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

Phase 2 trial results for an mRNA-1345 vaccine targeting Respiratory Syncytial Virus in children aged 2 to <18 at high risk; results completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease

Drugs mentioned

• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 2 | Status: COMPLETED | Results posted: 2026-08-18